{"schema_version":"secwatch.filing_event.v1","accession":"0001650664-24-000034","form_type":"8-K","ticker":"EDIT","cik":"0001650664","company_name":"Editas Medicine, Inc.","filed_at":"2024-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.428653+00:00","generated_at":"2026-06-02T10:33:44.850593+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Editas Medicine Q1 net loss $62M; cash $376.8M; reni-cel adult cohort enrollment complete","bullets":["Q1 2024 net loss $62.0M ($0.76/share) vs $49.0M ($0.71) in Q1 2023; collaboration revenue fell to $1.1M from $9.9M.","Cash, equivalents, and marketable securities $376.8M at March 31, 2024; runway into 2026.","R&D expenses rose to $48.8M from $37.8M driven by reni-cel clinical and manufacturing costs.","Completed adult cohort enrollment in RUBY trial for sickle cell disease; enrolled multiple adolescent patients.","Extended Bristol Myers Squibb collaboration by two years; CAFC oral arguments held for CRISPR patent interference."],"urls":{"canonical":"https://secwatch.observer/filing/0001650664-24-000034","json":"https://secwatch.observer/filing/0001650664-24-000034.json","markdown":"https://secwatch.observer/filing/0001650664-24-000034.md","text":"https://secwatch.observer/filing/0001650664-24-000034.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1650664/000165066424000034/0001650664-24-000034-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1650664/000165066424000034/edit-20240508.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T10:33:44.850593+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d03e861074cc95adb619081676607acfcd5b98f9","claim":"Editas Medicine, Inc. reported first quarter 2024 results: net income net loss of $62.0 million, EPS -$0.76.","evidence_excerpt":"For the three months ended March 31, 2024, net loss attributable to common stockholders was $62.0 million, or $0.76 per share, compared to net loss of $49.0 million, or $0.71 per share, for the same period in 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1650664/000165066424000034/0001650664-24-000034-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter 2024"},{"label":"Net income","value":"net loss of $62.0 million"},{"label":"EPS","value":"-$0.76"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}